| Literature DB >> 33479781 |
Klervi Leuraud1, David B Richardson2, Elisabeth Cardis3,4,5, Robert D Daniels6, Michael Gillies7, Richard Haylock7, Monika Moissonnier8, Mary K Schubauer-Berigan8, Isabelle Thierry-Chef3,4,5, Ausrele Kesminiene8, Dominique Laurier9.
Abstract
The Life Span Study (LSS) of Japanese atomic bomb survivors has served as the primary basis for estimates of radiation-related disease risks that inform radiation protection standards. The long-term follow-up of radiation-monitored nuclear workers provides estimates of radiation-cancer associations that complement findings from the LSS. Here, a comparison of radiation-cancer mortality risk estimates derived from the LSS and INWORKS, a large international nuclear worker study, is presented. Restrictions were made, so that the two study populations were similar with respect to ages and periods of exposure, leading to selection of 45,625 A-bomb survivors and 259,350 nuclear workers. For solid cancer, excess relative rates (ERR) per gray (Gy) were 0.28 (90% CI 0.18; 0.38) in the LSS, and 0.29 (90% CI 0.07; 0.53) in INWORKS. A joint analysis of the data allowed for a formal assessment of heterogeneity of the ERR per Gy across the two studies (P = 0.909), with minimal evidence of curvature or of a modifying effect of attained age, age at exposure, or sex in either study. There was evidence in both cohorts of modification of the excess absolute risk (EAR) of solid cancer by attained age, with a trend of increasing EAR per Gy with attained age. For leukemia, under a simple linear model, the ERR per Gy was 2.75 (90% CI 1.73; 4.21) in the LSS and 3.15 (90% CI 1.12; 5.72) in INWORKS, with evidence of curvature in the association across the range of dose observed in the LSS but not in INWORKS; the EAR per Gy was 3.54 (90% CI 2.30; 5.05) in the LSS and 2.03 (90% CI 0.36; 4.07) in INWORKS. These findings from different study populations may help understanding of radiation risks, with INWORKS contributing information derived from cohorts of workers with protracted low dose-rate exposures.Entities:
Keywords: A-bomb survivors; Cancer; Epidemiology; Ionizing radiation; Low dose; Low dose-rate; Nuclear workers
Mesh:
Year: 2021 PMID: 33479781 PMCID: PMC7902587 DOI: 10.1007/s00411-020-00890-7
Source DB: PubMed Journal: Radiat Environ Biophys ISSN: 0301-634X Impact factor: 2.017
Impact of selection criteria on numbers of individuals in the Life Span Study and in INWORKS
| Number of individuals | Life Span Study | INWORKS |
|---|---|---|
| Initially in the respective studies | 86,611 | 308,297 |
| Remaining after exclusion of individuals | ||
| Firstly, exposed[ | 86,611 | 305,150 |
| Then, exposed[ | 51,215 | 267,031 |
| Then, exposed[ | 45,625 | 265,144 |
| Then, born before 1886 | 45,625 | 265,131 |
| Then, dead or lost to follow-up within 5 years after exposure[ | 45,625 | 259,350 |
First monitored in INWORKS
Age at bombings in the LSS
Characteristics of the Life Span Study and INWORKS subsets used for comparison
| Life Span Study | INWORKS | |
|---|---|---|
| Period of exposure | 1945 | 1945–2005 |
| Period of follow-up | 1950–2003 | 1950–2005 |
| Percentage of males | 36% | 88% |
| Age at exposure[ | 37.3 [20.1; 59.9] | 37.7 [19.4; 71.5] |
| Attained age (years), mean [range] | 65.9 [27.6; 112.1] | 60.0 [25.5; 112.3] |
| Colon dose[ | 115.7 [0.0; 2,905.2] | 19.2 [0.0; 1,237.1] |
| Percentage of individuals with colon dose[ | 78% | 96% |
| Red bone marrow dose[ | 134.3 [0.0; 3,630.0] | 17.6 [0.0; 1,131.5] |
| Person-years (millions) | 1.48 | 6.18 |
| Causes of deaths | ||
| All causes, | 37,943 (83.2%) | 59,118 (22.8%) |
| Solid cancer, | 7982 (21.0%) | 16,279 (27.5%) |
| Leukemia,[ | 196 (0.5%) | 464 (0.8%) |
Age at atomic bombings in the LSS; age at mid-period of radiation monitoring in INWORKS
Weighted absorbed dose including a neutron contribution in the LSS
Cumulative dose without any neutron contribution in INWORKS
Excluding chronic lymphocytic leukemia in INWORKS
Excess deaths from solid cancer per categories of 5-year lagged colon dose in subsets of the Life Span Study and INWORKS
| Life Span Study | INWORKS | |||||||
|---|---|---|---|---|---|---|---|---|
| 5-year lagged colon dose (mGy) | Mean colon dose | Person-years (/103) | Observed deaths | Fitted[ | Mean colon dose[ | Person-years (/103) | Observed deaths | Fitted[ |
| < 5 | 1.0 | 650.5 | 3414 | 1.3 | 1.0 | 3842.5 | 8274 | 3.0 |
| 5–20− | 10.5 | 241.6 | 1258 | 5.1 | 10.7 | 1220.3 | 3717 | 12.0 |
| 20–60− | 36.8 | 182.4 | 945 | 13.4 | 34.7 | 680.4 | 2309 | 23.6 |
| 60–100− | 78.3 | 84.3 | 452 | 13.1 | 77.0 | 200.3 | 794 | 17.1 |
| 100–200− | 143.1 | 107.6 | 595 | 31.6 | 138.0 | 160.8 | 738 | 28.0 |
| 200–300− | 249.2 | 54.1 | 309 | 26.6 | 241.0 | 45.7 | 247 | 17.7 |
| 300–500− | 389.5 | 61.9 | 342 | 47.8 | 370.3 | 23.4 | 156 | 16.3 |
| 500–1,000− | 697.0 | 59.7 | 371 | 77.4 | 617.5 | 4.7 | 43 | 6.2 |
| ≥ 1,000 | 1576.5 | 38.2 | 296 | 104.7 | 1125.8 | 0.2 | 1 | 0.5 |
Cumulative
Under a simple linear excess relative rate model (weighted average over sex for the LSS with a weight of 0.88 for males and 0.12 for females, no modifying effect of age)
Parameter estimates of the excess relative rate (ERR) and excess absolute rate (EAR) models for solid cancer and 5-year lagged colon dose in subsets of the life span study and INWORKS
| Life Span Study | INWORKS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose coefficient at 1 Gy | 90% Cl | Deviance | Dose coefficient at 1 Gy | 90% Cl | Deviance | |||||
| ERR model[ | ||||||||||
| ERR( | 12,404.9 | 29,058 | 5541.4 | 11,006 | ||||||
| β1: linear | 0.28 | 0.18; 0.38 | 0.29 | 0.07; 0.53 | ||||||
| ERR( | 12,404.6 | 29,057 | 0.548[ | 5541.3 | 11,005 | 0.909[ | ||||
| | 0.23 | 0.10; 0.40 | 0.27 | −0.14; 0.68 | ||||||
| | 0.03 | −0.05; 0.10 | 0.06 | −0.78; 1.04 | ||||||
| ERR( | 12,401.1 | 29,056 | 0.147[ | 5,539.0 | 11,004 | 0.307[ | ||||
| ERR/Gy at attained age < 60 years | 0.35 | 0.19; 0.57 | 0.35 | −0.26; 1.04 | ||||||
| ERR/Gy at attained age 60– < 80 years | 0.31 | 0.20; 0.43 | 0.19 | −0.05; 0.46 | ||||||
| ERR/Gy at attained age 80+ years | 0.16 | 0.06; 0.29 | 0.86 | 0.20; 1.61 | ||||||
| EAR model[ | ||||||||||
| EAR( | 12,831.6 | 29,395 | 6329.2 | 11,848 | ||||||
| | 8.03 | 3.74; 13.07 | 1.68 | < 0; 7.55 | ||||||
| EAR( | 12,812.4 | 29,393 | < 0.001[ | 6322.1 | 11,846 | 0.029[ | ||||
| EAR/Gy at attained age < 60 years | 5.84 | 3.07; 9.50 | 0.42 | < 0; 6.10 | ||||||
| EAR/Gy at attained age 60– < 80 years | 20.79 | 11.56; 31.55 | 13.86 | −4.34; 33.16 | ||||||
| EAR/Gy at attained age 80+ years | 33.27 | 13.85; 60.23 | 190.40 | 58.67; 334.9 | ||||||
CI likelihood-based confidence interval
Defined as λ0(c,s,b,a)[1 + ERR(d,a)], where d is colon dose (cumulative in INWORKS), c is city for the LSS and country for INWORKS, s is sex, b is birth year, a is attained age in three categories (< 60, 60–80, 80+ years)
Defined as λ0(c,s,b,a) + EAR(d,a), the dose coefficients in the EAR model describe the excess cases per 10,000 person-years per 1 Gy
The LSS ERR and EAR estimates are weighted averages over sex with a weight of 0.88 for males and 0.12 for females
P: p value of a likelihood ratio test vs. cβ2 = 0 or dυ = 0
< 0: lower CI bound not estimated (on the boundary of the parameter space)
Excess relative rate (ERR) of solid cancer per gray for restricted 5-year lagged colon dose ranges in subsets of the Life Span Study and INWORKS
| Colon dose[ | ||||||
|---|---|---|---|---|---|---|
| 0–100 mGy | 0–200 mGy | 0–300 mGy | 0–500 mGy | 0–1000 mGy | Whole | |
| Mean colon dose | 14.2 | 25.2 | 34.4 | 50.2 | 77.0 | 115.7 |
| Person-years | 1,158,870 | 1,266,440 | 1,320,560 | 1,382,440 | 1,442,100 | 1,480,340 |
| Observed deaths | 6069 | 6664 | 6973 | 7315 | 7686 | 7982 |
| ERR/Gy | 0.38 | 0.50 | 0.45 | 0.25 | 0.24 | 0.28 |
| 90% CI | −0.27; 1.07 | 0.17; 0.86 | 0.21; 0.70 | 0.11; 0.41 | 0.15; 0.34 | 0.18; 0.38 |
| 0.343 | 0.011 | 0.001 | 0.004 | < 0.001 | < 0.001 | |
| Fitted excess deaths[ | 45.0 | 116.8 | 146.8 | 128.0 | 191.4 | 321.1 |
| Mean colon dose | 9.4 | 12.8 | 14.5 | 15.9 | 16.3 | 16.4 |
| Person-years | 5,943,550 | 6,104,410 | 6,150,100 | 6,173,470 | 6,178,150 | 6,178,320 |
| Observed deaths | 15,094 | 15,832 | 16,079 | 16,235 | 16,278 | 16,279 |
| ERR/Gy | 0.49 | 0.63 | 0.32 | 0.26 | 0.31 | 0.29 |
| 90% CI | −0.21; 1.23 | 0.21; 1.07 | 0.01; 0.65 | 0.01; 0.52 | 0.09; 0.54 | 0.07; 0.53 |
| 0.253 | 0.012 | 0.092 | 0.091 | 0.021 | 0.026 | |
| Fitted excess deaths[ | 93.5 | 179.4 | 111.8 | 102.5 | 129.7 | 124.3 |
CI likelihood-based confidence interval
Cumulative dose in INWORKS
Likelihood ratio test
Under a linear ERR model (no modifying effect of age)
The LSS ERR and fitted excess estimates are weighted averages over sex with a weight of 0.88 for males and 0.12 for females; sex-averaged estimates for the restricted dose ranges were obtained by fixing the parameter for effect modification by sex to the value for that parameter obtained when fitting the model to the full-dose range
Excess deaths from leukemia* per categories of 5-year lagged dose in subsets of the Life Span Study and INWORKS
| Life Span Study | INWORKS | |||||||
|---|---|---|---|---|---|---|---|---|
| Dose[ | Mean RBM dose (mGy) | Person-years (/103) | Observed deaths | Fitted[ | Mean RBM dose (mGy) | Person-years (/103) | Observed deaths | Fitted[ |
| < 5 | 1.1 | 650.5 | 66 | 0.2 | 1.0 | 3842.5 | 237 | 0.8 |
| 5–20− | 11.9 | 241.6 | 28 | 0.8 | 9.7 | 1220.3 | 102 | 3.1 |
| 20–60− | 41.8 | 182.4 | 19 | 2.3 | 31.8 | 680.4 | 58 | 5.7 |
| 60–100− | 89.3 | 84.3 | 7 | 2.3 | 70.5 | 200.3 | 25 | 4.1 |
| 100–200− | 164.0 | 107.6 | 7 | 5.4 | 126.1 | 160.8 | 24 | 6.8 |
| 200–300− | 284.9 | 54.1 | 10 | 4.6 | 220.2 | 45.7 | 11 | 4.1 |
| 300–500− | 450.0 | 61.9 | 9 | 8.4 | 338.4 | 23.4 | 6 | 3.4 |
| 500–1000− | 807.6 | 59.7 | 15 | 13.8 | 564.2 | 4.7 | 1 | 1.0 |
| ≥1000 | 1857.6 | 38.2 | 35 | 19.7 | 1026.6 | 0.2 | 0 | 0.1 |
Excluding chronic lymphocytic leukemia in INWORKS
RBM red bone marrow
Cumulative dose in INWORKS
Under a simple linear excess relative rate model (the LSS estimates are weighted averages over sex with a weight of 0.88 for males and 0.12 for females, no modifying effect of age)
Parameter estimates of the excess relative rate (ERR) and excess absolute rate (EAR) models for leukemia* and 5-year lagged red bone marrow dose in subsets of the Life Span Study and INWORKS
| Life Span Study | INWORKS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose coefficient at 1 Gy | 90% CI | Deviance | Dose coefficient at 1 Gy | 90% CI | Deviance | |||||
| ERR model[ | ||||||||||
| ERR( | 1284.4 | 29,058 | 1235.0 | 11,006 | ||||||
| | 2.75 | 1.73; 4.21 | 3.15 | 1.12; 5.72 | ||||||
| ERR( | 1272.1 | 29,057 | < 0.001[ | – | – | – | ||||
| | 0.10 | −1.03; 1.49 | NC | – | ||||||
| | 1.61 | 0.81; 2.68 | NC | – | ||||||
| ERR( | 1280.1 | 29,056 | 0.111[ | 1,233.5 | 11,004 | 0.472[ | ||||
| ERR/Gy at attained age < 60 years | 4.57 | 2.41; 8.45 | −0.04 | < 0; 5.21 | ||||||
| ERR/Gy at attained age 60– < 80 years | 2.48 | 1.32; 4.29 | 3.71 | 1.15; 7.15 | ||||||
| ERR/Gy at attained age 80+ years | 1.21 | 0.25; 3.15 | 5.07 | −0.19; 15.07 | ||||||
| EAR model[ | ||||||||||
| EAR( | 1599.2 | 29,409 | 1733.7 | 11,863 | ||||||
| | 3.54 | 2.30; 5.05 | 2.03 | 0.36; 4.07 | ||||||
| EAR( | 1598.1 | 29,407 | 0.564[ | 1729.2 | 11,861 | 0.104[ | ||||
| EAR/Gy at attained age < 60 years | 2.98 | 1.74; 4.67 | 1.11 | < 0; 3.18 | ||||||
| EAR/Gy at attained age 60– < 80 years | 4.15 | 2.46; 6.37 | 4.80 | 1.12; 9.23 | ||||||
| EAR/Gy at attained age 80+ years | 4.53 | 1.28; 10.00 | 27.01 | 1.80; 63.22 | ||||||
Excluding chronic lymphocytic leukemia in INWORKS
NC convergence not achieved
Defined as λ0(c,s,b,a)[1 + ERR(d,a)], where d is red bone marrow dose, c is city for the LSS and country for INWORKS, s is sex, b is birth year, a is attained age in three categories (< 60, 60–80, 80+ years)
Defined as λ0(c,s,b,a) + EAR(d,a), the dose coefficients in the EAR model describe the excess cases per 10,000 person-years per 1 Gy
The LSS ERR and EAR estimates are weighted averages over sex with a weight of 0.88 for males and 0.12 for females. CI: likelihood-based confidence interval
P value of a likelihood ratio test vs cβ2 = 0 or dυ = 0
< 0: lower CI bound not estimated (on the boundary of the parameter space)
Excess relative rate (ERR) of leukemia* per gray for restricted 5-year lagged dose ranges in subsets of the Life Span Study and INWORKS
| Dose[ | ||||||
|---|---|---|---|---|---|---|
| 0–100 mGy | 0–200 mGy | 0–300 mGy | 0–500 mGy | 0–1000 mGy | Whole | |
| Mean RBM dose | 16.2 | 28.7 | 39.2 | 57.6 | 88.6 | 134.3 |
| Person-years | 1,158,870 | 1,266,440 | 1,320,560 | 1,382,440 | 1,442,100 | 1,480,340 |
| Observed deaths | 120 | 127 | 137 | 146 | 161 | 196 |
| ERR/Gy | −2.18 | −1.93 | 0.43 | 0.59 | 1.15 | 2.75 |
| 90% CI | −5.56; 3.25 | < 0; 0.27 | −0.93; 2.44 | −0.43; 2.03 | 0.37; 2.22 | 1.73; 4.21 |
| 0.455 | 0.139 | 0.652 | 0.381 | 0.008 | < 0.001 | |
| Fitted excess deaths[ | −5.1 | −8.7 | 2.7 | 5.6 | 17.0 | 57.6 |
| Mean RBM dose | 8.6 | 11.7 | 13.3 | 14.5 | 14.9 | 14.9 |
| Person-years | 5,943,550 | 6,104,410 | 6,150,100 | 6,173,470 | 6,178,150 | 6,178,320 |
| Observed deaths | 422 | 446 | 457 | 463 | 464 | 464 |
| ERR/Gy | 4.24 | 3.61 | 3.79 | 3.46 | 3.21 | 3.15 |
| 90% CI | −0.71; 10.47 | 0.47; 7.54 | 1.25; 6.99 | 1.29; 6.19 | 1.16; 5.80 | 1.12; 5.72 |
| 0.166 | 0.054 | 0.009 | 0.004 | 0.005 | 0.006 | |
| Fitted excess deaths[ | 18.1 | 23.2 | 29.4 | 30.6 | 29.5 | 29.1 |
Excluding chronic lymphocytic leukemia in INWORKS
Cumulative dose in INWORKS
Likelihood ratio test
Under a linear ERR model (no modifying effect of age)
RBM: red bone marrow. CI: likelihood-based confidence interval
The LSS ERR and fitted excess estimates are weighted averages over sex with a weight of 0.88 for males and 0.12 for females; sex-averaged estimates for the restricted dose ranges were obtained by fixing the parameter for effect modification by sex to the value for that parameter obtained when fitting the model to the full-dose range